Blockade of cannabinoid 1 receptor improves glucose responsiveness in pancreatic beta cells.

Citation data:

Journal of cellular and molecular medicine, ISSN: 1582-4934, Vol: 22, Issue: 4, Page: 2337-2345

Publication Year:
2018
Captures 1
Readers 1
Citations 1
Citation Indexes 1
Repository URL:
https://onlinelibrary.wiley.com/doi/abs/10.1111/jcmm.13523
PMID:
29431265
DOI:
10.1111/jcmm.13523
Author(s):
Shin, Hanho; Han, Ji Hye; Yoon, Juhwan; Sim, Hyo Jung; Park, Tae Joo; Yang, Siyoung; Lee, Eun Kyung; Kulkarni, Rohit N; Egan, Josephine M; Kim, Wook
Publisher(s):
Wiley
Tags:
Biochemistry, Genetics and Molecular Biology; beta-cell function; cannabinoid 1 receptor; glucokinase; glucose transporter 2; insulin secretion
article description
Cannabinoid 1 receptors (CB1Rs) are expressed in peripheral tissues, including islets of Langerhans, where their function(s) is under scrutiny. Using mouse β-cell lines, human islets and CB1R-null (CB1R ) mice, we have now investigated the role of CB1Rs in modulating β-cell function and glucose responsiveness. Synthetic CB1R agonists diminished GLP-1-mediated cAMP accumulation and insulin secretion as well as glucose-stimulated insulin secretion in mouse β-cell lines and human islets. In addition, silencing CB1R in mouse β cells resulted in an increased expression of pro-insulin, glucokinase (GCK) and glucose transporter 2 (GLUT2), but this increase was lost in β cells lacking insulin receptor. Furthermore, CB1R mice had increased pro-insulin, GCK and GLUT2 expression in β cells. Our results suggest that CB1R signalling in pancreatic islets may be harnessed to improve β-cell glucose responsiveness and preserve their function. Thus, our findings further support that blocking peripheral CB1Rs would be beneficial to β-cell function in type 2 diabetes.